Weber Shandwick wins Lipitor account

Share this article:
Pfizer named Weber Shandwick PR agency of record for Lipitor following a break with WPP. Weber Shandwick was recently appointed agency of record for the firm's statin torcetrapib/atorvastatin.

The award, first reported in PRWeek, follows a review pitting Weber Shandwick, an Interpublic Group agency, against Omnicom's Fleishman-Hillard, WPP's GCI Group and independent APCO Worldwide.

In October, Pfizer parted ways with WPP network consortium WPP Health Success, which had handled the Lipitor, Norvasc and Caduet business globally for over two years. WPP Health Success did not pitch for the Lipitor business. WPP's Feinstein Kean continues to support Caduet in the US and Burson-Marsteller handles the brand globally.

The shift comes amid a series of frantic news cycles for the world's best-selling drug and its prospective follow-on. The American Heart Association, miffed that Pfizer released data ahead of its scheduled presentation at the group's conference, cancelled the slot altogether. More importantly, the data released showed that the new drug does elevate blood pressure, however minimally. Meanwhile, Pfizer won an appeals court ruling preserving Lipitor's patent exclusivity for three more years.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.